{"id":"integrase-strand-transfer-inhibitors","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Elevated creatine kinase"}]},"_chembl":{"chemblId":"CHEMBL264030","moleculeType":"Small molecule","molecularWeight":"1259.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs inhibit the integrase enzyme, which HIV uses to integrate its RNA genome into the human host cell chromosome. By blocking this critical step in the viral replication cycle, the drugs prevent establishment of persistent infection and reduce viral load. This class represents a major advance in antiretroviral therapy with a distinct mechanism from reverse transcriptase and protease inhibitors.","oneSentence":"Integrase strand transfer inhibitors block HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:16.594Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment-naïve and treatment-experienced patients)"},{"name":"HIV-1 infection in combination antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT05652478","phase":"PHASE2","title":"Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Healthy Volunteer, Weight Gain, Metabolic Effects","enrollment":120},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT04636437","phase":"PHASE4","title":"Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2021-07-27","conditions":"HIV Infections","enrollment":147},{"nctId":"NCT06829082","phase":"","title":"Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia","status":"COMPLETED","sponsor":"Servicios de Salud IPS Suramericana S.A.S","startDate":"2024-11-15","conditions":"HIV Treatment","enrollment":161},{"nctId":"NCT04019873","phase":"","title":"'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-18","conditions":"HIV Infections","enrollment":774},{"nctId":"NCT02429791","phase":"PHASE3","title":"Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-04-14","conditions":"HIV Infections","enrollment":510},{"nctId":"NCT02422797","phase":"PHASE3","title":"Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-04-21","conditions":"HIV Infections","enrollment":518},{"nctId":"NCT06485154","phase":"PHASE4","title":"Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2024-06-01","conditions":"HIV Prevention","enrollment":100},{"nctId":"NCT04805944","phase":"","title":"Gut Microbiota, PGx and INSTIs Response","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2021-03-10","conditions":"HIV Infections","enrollment":180},{"nctId":"NCT03835546","phase":"","title":"Study to Assess the ART Impact on the Brain Outcomes. The ARBRE Study","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2015-10-26","conditions":"HIV-1 Infection, Cognitive Impairment","enrollment":45},{"nctId":"NCT04892654","phase":"PHASE3","title":"Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch","status":"RECRUITING","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2022-08-17","conditions":"HIV-1-infection","enrollment":150},{"nctId":"NCT04460924","phase":"","title":"ARTiBIOME: Observational Study on the Effect of HIV and ART on Gut Microbiome","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2020-11-01","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT04675255","phase":"NA","title":"Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-01-01","conditions":"HIV I Infection, Adiposity","enrollment":8},{"nctId":"NCT02924389","phase":"PHASE4","title":"Dolutegravir in Reservoirs","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"HIV","enrollment":22},{"nctId":"NCT04302896","phase":"EARLY_PHASE1","title":"Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs","status":"COMPLETED","sponsor":"Rhonda Brand","startDate":"2020-08-31","conditions":"Medication Adherence, HIV","enrollment":30},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":808,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["INSTI"],"phase":"marketed","status":"active","brandName":"Integrase strand transfer inhibitors","genericName":"Integrase strand transfer inhibitors","companyName":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","companyId":"fundacion-para-la-investigacion-biomedica-del-hospital-universitario-ramon-y-caj","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Integrase strand transfer inhibitors block HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA. Used for HIV-1 infection (treatment-naïve and treatment-experienced patients), HIV-1 infection in combination antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}